Please activate JavaScript!
Please install Adobe Flash Player, click here for download

EH 1_2015

Further information available on: The biggest is its versatility. And its size. RadiForce™ RX850. The RX850 displays images from multiple imaging processes simul- taneously on its 31.1“, 8-megapixel LCD screen, making it highly flexible and completely versatile. The RX850 is available with an optional anti-reflective (AR) optical coating, which prevents glare without diffusing the light from the screen. Suitable for mammography in accordance with DIN 6868-157 Flexible hanging protocol due to high resolution Fine dot pitch for sharper detail Low heat output keeps room temperature pleasantly low Anti-reflective screen for improved ergonomic performance 5 year warranty EIZO•Anzeige RX850 Mammo•European Hospital•210x297mm + 3mm•ICv2•DU:17.02.15 eizME5021_RadiForce_AZ_RX850_Mammo_A4_OM_European_Hospital_EN_ICv2_1ml.indd 1 11.02.15 15:48 17EH @ ECR th DRX estimated BMD (bone mineral den- sity). The BMD is then correlated with that of the population of the same age group and additionally with the estimated peak bone mass point, i.e. the point in time at which all humans have their highest bone density, around the age of 30. In this way we create several comparisons and reference points for individual assessment.’ A huge reference database, com- piled from different worldwide studies, is used as the basis for all those measurement. Naturally, the results of every examination fed into the OneScreen system in turn enhance this reference database. The OneScreen system is FDA approved, has the CE mark and is available to all users of low dose mammography. Currently, the only hindrance for the procedure’s comprehensive uti- lisation is the lack of reimbursement by the statutory health insurers in European countries. However, due to the comparatively small financial contribution required from patients the method doesn’t lose its overall attractiveness. Source: Sectra er screening The enhancement of mMRI through PET constitutes a further quantum leap for the implemen- tation of personalised medicine. Fluorodeoxyglucose (18F-FDG) PET measures the glucose metabo- lism, which increases in tumour tissue compared to normal cells. Additionally, PET allows precise imaging using specific radiotracers. These can capture different, relevant processes of tumour development, progression and therapy response, such as tumour hypoxia, apoptosis, cell proliferation or receptor den- sity. ‘In a recent study, our Working Group showed that PET-MRI facili- tates improved, non-invasive differ- entiation of benign and malignant breast cancers. The procedure can achieve a reduction in the rate of unnecessary biopsies by 50%,’ the professor confirmed. Despite all its advantages, breast- MRI, which resulted from pioneer- ing work by two German radiolo- gists i.e. Professors Sylvia Heywang Köbrunner and Werner Kaiser – who unfortunately passed away far too early – currently doesn’t fare too well in its ‘homeland’, a devel- opment that Prof. Helbich views critically. Undoubtedly, breast MRI has not become a routine examina- tion but should be carried out when and where indicated. However, the wide range of indications for breast MRI should not be limited by an evidence-based view of medicine with a limited focus. ‘Breast MRI is of benefit for pre-operative staging, such as for invasive lobular cancers and for non-invasive ductal cancers. It is also successfully being utilised for neo-adjuvant chemotherapy and is undisputedly the best method to differentiate between scar tissue and recurrence. Furthermore, it is also the best procedure for high risk screening,’ he added: ‘In particular, the data for high risk screening with MRI show that a large propor- tion of clinically significant breast cancers are detected far too late with mammography and ultrasound compared to MRI scanning. Therefore it’s no surprise that some countries are already consid- ering considerably shortening the MRI protocols for breast imaging and establishing MRI for screening in place of mammography.’ Dr Thomas H Helbich MSc MNA is a professor and Vice Chairman of the University Department of Radiology and Nuclear Medicine at the Medical University of Vienna. As an expert in breast cancer diagnosis he was previously in charge of the Breast Imaging Department at the University of Toronto. He is also a past-president of the European Society of Breast Imaging (EUSOBI) and the Austrian Society of Senology (ÖGS) (2009-2011) MedUniVienna/Matern eizME5021_RadiForce_AZ_RX850_Mammo_A4_OM_European_Hospital_EN_ICv2_1ml.indd 111.02.1515:48

Pages Overview